Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
After Failing Phase IIb Study, Company Adds Phase III Trial
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
